{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:35:10Z","timestamp":1786563310417,"version":"build-2736575974"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Plasma cell leukemia and central nervous system involvement are two poor prognostic factors in myeloma, and such patients are often excluded from clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Case<\/jats:title>\n A 59\u2010year\u2010old patient with primary plasma cell leukemia developed leptomeningeal CNS disease following autologous transplant. Intrathecal chemotherapy and selinexor, pomalidomide, and dexamethasone failed to clear cerebrospinal fluid plasma cells.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Elranatamab achieved complete serological and CNS response. The patient recovered from bedbound status to full independence and proceeded to receive CAR\u2010T therapy. At 8 months post CAR\u2010T, he remains in sustained MRD negativity.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Sequential bispecific antibody and CAR\u2010T therapy demonstrates exceptional efficacy in CNS multiple myeloma, offering new hope for this historically terminal condition and supporting the systematic study of novel immunotherapies in high\u2010risk myeloma populations.<\/jats:p>\n \n Trial Registration<\/jats:bold>\n : The authors have confirmed clinical trial registration is not needed for this submission.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jha2.70203","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:51:34Z","timestamp":1772988694000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions"],"prefix":"10.1002","volume":"7","author":[{"given":"Kelley","family":"Julian","sequence":"first","affiliation":[{"name":"Division of Hematology Huntsman Cancer Institute University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Hematology Huntsman Cancer Institute University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology Huntsman Cancer Institute University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248518"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010015\u20102484\u2010y"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2395440"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014345"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70108"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1206715"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.036"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021221"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002482\u20106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000433"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029773"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:43:46Z","timestamp":1786113826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jha2.70203"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70203","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70203"}}